News & Events
 
The Drugs Technical Advisory Board has examined the issue of suspension of manufacture and sale of Pioglitazone on 19th July 2013 & has recommended that the Suspension of the drug should be revoked and allowed to be marketed subject to certain conditions the manufacturers shall mention on their package insert and promotional literature of the drug. Based on DTAB report Ministry of health & family welfare & Central Government revokes the notification G.S.R.379(E) dated 18th June 2013.
-------------------------------
A new study presented at EULAR 2013,the Annual Congress of the European League Against Rheumatism shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over the counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint Possible serious ADEs include gastrointestinal bleeding, peptic ulceration, high blood pressureand worsening heart failure.
-------------------------------
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.
-------------------------------
People taking statin drugs to lower their cholesterol may slightly increase their risk for muscle and joint diseases as well as strains and sprains, a new study suggests.The results were published online June 3 in the journal JAMA Internal Medicine.

Testimonials
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
 
     
 
Metoprolol  Succinate Extended - Release  Tablets USP
 
  COMPOSITION:  
  METOPROLOL PLAIN – 50 / 25mg  
     
  THERAPEUTIC INDICATIONS:  
 
Treatment of hypertension, Angina pectoris, Cardiac arrhythmias, Adjunct in hyperthyroidism,  Prophylaxis of migraine, Stable symptomatic heart failure, Emergency treatment of cardiac arrhythmias, Prophylaxis or control of arrhythmias on induction of ana esthesia, Adjunct in the early management of acute myocardial infarction.
 
     
  DOSAGE AND ADMINISTRATION:  
 
Hypertension
AdultConventional preparation: Initially, 50-100 mg daily in single or 2 divided doses; may increase wkly to 400 mg daily depending on response. Maintenance: 100-200 mg daily; up to 400 mg daily. Extended-release preparation: 25-100 mg once daily.
Angina pectoris
Adult50-100 mg bid-tid.
Cardiac arrhythmias
Adult50 mg bid-tid; increased to 300 mg daily in divided doses if needed.
Adjunct in hyperthyroidism
Adult50 mg 4 times daily.
Prophylaxis of migraine:
Adult100-200 mg daily in divided doses.
Stable symptomatic heart failure:
Adult: As a modified-release preparation of metoprolol succinate: Initially, 12.5-25 mg of equivalent metoprolol tartrate dose. Increase, as tolerated, at 2-wk intervals to a max of 20 mg once daily.
Emergency treatment of cardiac arrhythmias
Adult: Initially, up to 5 mg at a rate of 1-2 mg/min; may repeat at 5-minute intervals if needed up to a total dose of 10-15 mg. When acute arrhythmias are controlled, initiate maintenance therapy 4-6 hr after IV therapy using oral therapy not exceeding 50 mg tid.
Prophylaxis or control of arrhythmias on induction of anaesthesia
Adult: 2-4 mg as slow inj; may repeat injections of 2 mg as necessary up to a max total dose of 10 mg.
Adjunct in the early management of acute myocardial infarction
Adult: Admin within 12 hr of the onset of chest pain, 5 mg at 2-minute intervals to a total of 15 mg, if tolerated. After 15 minutes, for patients who have received full IV dose: Initiate oral therapy of 50 mg every 6 hr for 2 days; for patients who did not tolerate the full IV dose: Reduced oral dose should be given as and when their condition permits. Subsequent maintenance: 100 mg.
 
     
  CONTRAINDICATIONS :  
 
2nd or 3rd degree AV block; sick sinus syndrome; decompensated heart failure; clinically relevant sinus bradycardia. Severe peripheral arterial circulatory disorders. Cardiogenic shock. Asthma. Phaeochromocytoma (without α-blockade), systolic BP <100 mmHg. Metabolic acidosis. Pregnancy (2nd and 3rd trimesters).
 
     
  WARNINGS & PRECAUTIONS:  
 
Compensated heart failure, bronchospastic disease, hepatic impairment, AV conduction disorders, bradycardia, peripheral arterial circulatory disorders. An α-blocker should be given concurrently in patients with phaeochromocytoma. May mask signs of acute hypoglycaemia. May mask symptoms of hyperthyroidism. Caution when used in patients with history of cardiac failure or those with minimal cardiac reserve. Avoid using anaesthetic agents that may depress the myocardium. May impair ability to drive or operate machinery. Myasthenia gravis; history of psychiatric disorder. Lactation. Avoid abrupt drug withdrawal.
 
     
  Back to Products  

 

 

         
 
 
Home | About Us | Products | Enquiry | Contact Us | Order | Carrer
     
  All Rights Reserved By : Cadell Health care Pvt Ltd. Designed & Maintained By : Daffodil Design & Prints